<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Oct. 9, 2018 (HealthDay News) — Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher results in greater clearing of psoriasis versus placebo over 12 weeks, according to a phase 2 study published in the Oct. 4 issue of the New England Journal of Medicine<\/i>.<\/p>\n
Kim Papp, M.D., Ph.D., from K. Papp Clinical Research and Probity Medical Research in Peterborough, Ontario, Canada, and colleagues randomly assigned 267 patients to receive a TYK2 inhibitor, BMS-986165, orally (3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily) or placebo.<\/p>\n
The researchers found that at week 12, the percentage of patients with \u226575 percent reduction in the Psoriasis Area and Severity Index score was 7 percent (three of 45 patients) with placebo, 9 percent (four of 44 patients) with 3 mg of BMS-986165 every other day (P = 0.49 versus placebo), 39 percent (17 of 44 patients) with 3 mg daily (P < 0.001 versus placebo), 69 percent (31 of 45 patients) with 3 mg twice daily (P < 0.001 versus placebo), 67 percent (30 of 45 patients) with 6 mg twice daily (P < 0.001 versus placebo), and 75 percent (33 of 44 patients) with 12 mg daily (P < 0.001 versus placebo). For patients in the intervention group, there were three serious adverse events.<\/p>\n
“Larger and longer-duration trials of this drug are required to determine its safety and durability of effect in patients with psoriasis,” the authors write.<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including Bristol-Myers Squibb, which manufactures BMS-986165 and funded the study.<\/p>\n